

# David J Nutt

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/3010967/david-j-nutt-publications-by-year.pdf>

**Version:** 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

551  
papers

30,842  
citations

91  
h-index

156  
g-index

615  
ext. papers

36,802  
ext. citations

6.4  
avg, IF

7.49  
L-index

#	Paper	IF	Citations
551	Adverse effects of psychedelics: From anecdotes and misinformation to systematic science.. <i>Journal of Psychopharmacology</i> , <b>2022</b> , 2698811211069100	4.6	12
550	Increased global integration in the brain after psilocybin therapy for depression.. <i>Nature Medicine</i> , <b>2022</b> ,	50.5	9
549	Regulating the oxides of nitrogen [Dropping the myths. <i>Drug Science, Policy and Law</i> , <b>2022</b> , 8, 20503245221108521	10.8	1
548	Individual and combined effects of cannabidiol and $\Delta$ -tetrahydrocannabinol on striato-cortical connectivity in the human brain. <i>Journal of Psychopharmacology</i> , <b>2022</b> , 36, 732-744	4.6	0
547	GABA-A receptor differences in schizophrenia: a positron emission tomography study using [C]Ro154513. <i>Molecular Psychiatry</i> , <b>2021</b> , 26, 2616-2625	15.1	17
546	A Delphi-method-based consensus guideline for definition of treatment-resistant depression for clinical trials.. <i>Molecular Psychiatry</i> , <b>2021</b> ,	15.1	10
545	Medical cannabis for severe treatment resistant epilepsy in children: a case-series of 10 patients. <i>BMJ Paediatrics Open</i> , <b>2021</b> , 5, e001234	2.4	2
544	Ketamine for the treatment of mental health and substance use disorders: comprehensive systematic review.. <i>BJPsych Open</i> , <b>2021</b> , 8, e19	5	4
543	Psychedelic experience dose-dependently modulated by cannabis: results of a prospective online survey. <i>Psychopharmacology</i> , <b>2021</b> , 1	4.7	2
542	Alcohol and the Brain. <i>Nutrients</i> , <b>2021</b> , 13,	6.7	8
541	Study Protocol for "Psilocybin as a Treatment for Anorexia Nervosa: A Pilot Study". <i>Frontiers in Psychiatry</i> , <b>2021</b> , 12, 735523	5	5
540	A Multicriteria Decision Analysis Comparing Pharmacotherapy for Chronic Neuropathic Pain, Including Cannabinoids and Cannabis-Based Medical Products. <i>Cannabis and Cannabinoid Research</i> , <b>2021</b> ,	4.6	3
539	Self-blinding citizen science to explore psychedelic microdosing. <i>ELife</i> , <b>2021</b> , 10,	8.9	26
538	A risky business? Comparing the harms of alcohol and other recreational drugs. <i>Significance</i> , <b>2021</b> , 18, 40-42	0.5	
537	Functional evaluation of NK antagonism on cue reactivity in opiate dependence; An fMRI study. <i>Drug and Alcohol Dependence</i> , <b>2021</b> , 221, 108564	4.9	0
536	Some Contributions on How to Formulate Drug Policies and Provide Evidence-Based Regulation. <i>American Journal of Bioethics</i> , <b>2021</b> , 21, 28-31	1.1	1
535	Can pragmatic research, real-world data and digital technologies aid the development of psychedelic medicine?. <i>Journal of Psychopharmacology</i> , <b>2021</b> , 2698811211008567	4.6	12

534	Trial of Psilocybin versus Escitalopram for Depression. <i>New England Journal of Medicine</i> , <b>2021</b> , 384, 1402-1411	152	59.1
533	Putting the MD back into MDMA. <i>Nature Medicine</i> , <b>2021</b> , 27, 950-951	0	50.5
532	Developing a real-world evidence base for prescribed cannabis in the United Kingdom: preliminary findings from Project Twenty21. <i>Psychopharmacology</i> , <b>2021</b> , 1	6	4.7
531	A multi criteria decision analysis (MCDA) for evaluating and appraising government policy responses to non medical heroin use. <i>International Journal of Drug Policy</i> , <b>2021</b> , 91, 103180	4	5.5
530	Current controversies in medical cannabis: Recent developments in human clinical applications and potential therapeutics. <i>Neuropharmacology</i> , <b>2021</b> , 191, 108586	12	5.5
529	Acute effects of MDMA on trust, cooperative behaviour and empathy: A double-blind, placebo-controlled experiment. <i>Journal of Psychopharmacology</i> , <b>2021</b> , 35, 547-555	6	4.6
528	Imidazoline ligand BU224 reverses cognitive deficits, reduces microgliosis and enhances synaptic connectivity in a mouse model of Alzheimer's disease. <i>British Journal of Pharmacology</i> , <b>2021</b> , 178, 654-671	4	8.6
527	The Current Status of Psychedelics in Psychiatry. <i>JAMA Psychiatry</i> , <b>2021</b> , 78, 121-122	41	14.5
526	Chronic alcohol exposure differentially modulates structural and functional properties of amygdala: A cross-sectional study. <i>Addiction Biology</i> , <b>2021</b> , 26, e12980	1	4.6
525	The entropic tongue: Disorganization of natural language under LSD. <i>Consciousness and Cognition</i> , <b>2021</b> , 87, 103070	13	2.6
524	Therapeutic effects of classic serotonergic psychedelics: A systematic review of modern-era clinical studies. <i>Acta Psychiatrica Scandinavica</i> , <b>2021</b> , 143, 101-118	41	6.5
523	Medical cannabis and epilepsy in the UK [A qualitative analysis of the carers' perspective: We're asking for quality of life for our children] <i>Drug Science, Policy and Law</i> , <b>2021</b> , 7, 205032452110349	1	1.8
522	First study of safety and tolerability of 3,4-methylenedioxymethamphetamine-assisted psychotherapy in patients with alcohol use disorder. <i>Journal of Psychopharmacology</i> , <b>2021</b> , 35, 375-383	15	4.6
521	Sex differences in depressive symptoms and tolerability after treatment with selective serotonin reuptake inhibitor antidepressants: Secondary analyses of the GENPOD trial. <i>Journal of Psychopharmacology</i> , <b>2021</b> , 35, 919-927	0	4.6
520	Astrocyte reactivity with late-onset cognitive impairment assessed in vivo using C-BU99008 PET and its relationship with amyloid load. <i>Molecular Psychiatry</i> , <b>2021</b> ,	11	15.1
519	Acute acetate administration increases endogenous opioid levels in the human brain: A [C]carfentanil molecular imaging study. <i>Journal of Psychopharmacology</i> , <b>2021</b> , 35, 606-610	1	4.6
518	Therapeutic Alliance and Rapport Modulate Responses to Psilocybin Assisted Therapy for Depression.. <i>Frontiers in Pharmacology</i> , <b>2021</b> , 12, 788155	7	5.6
517	Debunking the myth of 'Blue Mondays': No evidence of affect drop after taking clinical MDMA.. <i>Journal of Psychopharmacology</i> , <b>2021</b> , 2698811211055809	0	4.6

- 516 Acute effects of cannabis on speech illusions and psychotic-like symptoms: two studies testing the moderating effects of cannabidiol and adolescence. *Psychological Medicine*, **2020**, 1-9 6.9 5
- 515 A Brief History of Psychopharmacology **2020**, 1-34
- 514 Psychiatric Drug Discovery and Development **2020**, 35-68 1
- 513 Neurotransmission and Mechanisms of Drug Action **2020**, 69-123
- 512 Pharmacodynamics and Pharmacokinetics **2020**, 124-150
- 511 Pharmacogenomics and Psychopharmacology **2020**, 151-202 2
- 510 Good Clinical Practice in Psychopharmacology **2020**, 203-203
- 509 Drugs to Treat Depression **2020**, 227-267
- 508 Drugs to Treat Anxiety and Insomnia **2020**, 268-289
- 507 Drugs to Treat Schizophrenia and Psychosis (Dopamine Antagonists and Partial Agonists Other Than Clozapine) **2020**, 290-325
- 506 Anticonvulsants for Mental Disorders: Valproate, Lamotrigine, Carbamazepine and Oxcarbazepine **2020**, 362-391
- 505 Drugs to Treat Attention Deficit Hyperactivity Disorder (ADHD) **2020**, 392-432 1
- 504 Drugs to Treat Dementia **2020**, 433-453
- 503 Drugs to Treat Substance Use Disorders **2020**, 454-494
- 502 Electroconvulsive Therapy and Neuromodulation Therapies **2020**, 495-495
- 501 Psychotropic Drug Treatment in Childhood and Adolescence **2020**, 525-542
- 500 Psychotropic Drug Treatment in Later Life **2020**, 543-576
- 499 Psychotropic Prescribing in Pregnancy and Lactation **2020**, 577-598

498	The Clinical Management of Acute Disturbance Including Rapid Tranquillisation <b>2020</b> , 599-618		
497	Antipsychotics, Weight Gain and Metabolic Risk <b>2020</b> , 619-619		
496	Medical cannabis in the UK: From principle to practice. <i>Journal of Psychopharmacology</i> , <b>2020</b> , 34, 931-937	4.6	11
495	Disturbances across whole brain networks during reward anticipation in an abstinent addiction population. <i>NeuroImage: Clinical</i> , <b>2020</b> , 27, 102297	5.3	5
494	The blind men and the elephant: Systematic review of systematic reviews of cannabis use related health harms. <i>European Neuropsychopharmacology</i> , <b>2020</b> , 33, 1-35	1.2	43
493	Therapeutic mechanisms of psilocybin: Changes in amygdala and prefrontal functional connectivity during emotional processing after psilocybin for treatment-resistant depression. <i>Journal of Psychopharmacology</i> , <b>2020</b> , 34, 167-180	4.6	36
492	Psychedelic Psychiatry's Brave New World. <i>Cell</i> , <b>2020</b> , 181, 24-28	56.2	77
491	DMT alters cortical travelling waves. <i>ELife</i> , <b>2020</b> , 9,	8.9	13
490	New psychoactive substances: Pharmacology influencing UK practice, policy and the law. <i>British Journal of Clinical Pharmacology</i> , <b>2020</b> , 86, 445-451	3.8	7
489	The development and validation of a human screening model of tobacco abstinence. <i>Drug and Alcohol Dependence</i> , <b>2020</b> , 206, 107720	4.9	1
488	Serotonin release measured in the human brain: a PET study with [ <sup>11</sup> C]CIMBI-36 and d-amphetamine challenge. <i>Neuropsychopharmacology</i> , <b>2020</b> , 45, 804-810	8.7	17
487	So near yet so far: why won't the UK prescribe medical cannabis?. <i>BMJ Open</i> , <b>2020</b> , 10, e038687	3	13
486	Blunted endogenous opioid release following an oral dexamphetamine challenge in abstinent alcohol-dependent individuals. <i>Molecular Psychiatry</i> , <b>2020</b> , 25, 1749-1758	15.1	12
485	Manifesto for an international digital mental health network <b>2019</b> , 2, 14-24		11
484	Imidazoline 2 binding sites reflecting astroglia pathology in Parkinson's disease: an in vivo [ <sup>11</sup> C]-BU99008 PET study. <i>Brain</i> , <b>2019</b> , 142, 3116-3128	11.2	35
483	Tapering of SSRI treatment to mitigate withdrawal symptoms. <i>Lancet Psychiatry</i> , <b>2019</b> , 6, 560-561	23.3	2
482	Dynamical exploration of the repertoire of brain networks at rest is modulated by psilocybin. <i>NeuroImage</i> , <b>2019</b> , 199, 127-142	7.9	53
481	Spectral signatures of serotonergic psychedelics and glutamatergic dissociatives. <i>NeuroImage</i> , <b>2019</b> , 200, 281-291	7.9	21

480	The Australian drug harms ranking study. <i>Journal of Psychopharmacology</i> , <b>2019</b> , 33, 759-768	4.6	48
479	Why medical cannabis is still out of patients' reach-an essay by David Nutt. <i>BMJ, The</i> , <b>2019</b> , 365, l1903	5.9	8
478	Alcohol Hangover: Underlying Biochemical, Inflammatory and Neurochemical Mechanisms. <i>Alcohol and Alcoholism</i> , <b>2019</b> , 54, 196-203	3.5	21
477	Why Less Is Always More in the Treatment of Alcohol Use Disorders. <i>JAMA Psychiatry</i> , <b>2019</b> , 76, 359-360	14.5	6
476	A Review of 3,4-methylenedioxymethamphetamine (MDMA)-Assisted Psychotherapy. <i>Frontiers in Psychiatry</i> , <b>2019</b> , 10, 138	5	42
475	First study of safety and tolerability of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy in patients with alcohol use disorder: preliminary data on the first four participants. <i>BMJ Case Reports</i> , <b>2019</b> , 12,	0.9	13
474	Microdosing psychedelics: More questions than answers? An overview and suggestions for future research. <i>Journal of Psychopharmacology</i> , <b>2019</b> , 33, 1039-1057	4.6	60
473	Should the supply of cannabis be legalised now?. <i>BMJ, The</i> , <b>2019</b> , 366, l4473	5.9	3
472	British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders: An update. <i>Journal of Psychopharmacology</i> , <b>2019</b> , 33, 923-947	4.6	98
471	Psychedelic drugs-a new era in psychiatry??. <i>Dialogues in Clinical Neuroscience</i> , <b>2019</b> , 21, 139-147	5.7	27
470	Compound asset sharing initiatives between pharmaceutical companies, funding bodies, and academia: Learnings and successes. <i>Pharmacology Research and Perspectives</i> , <b>2019</b> , 7, e00510	3.1	4
469	Neural correlates of the DMT experience assessed with multivariate EEG. <i>Scientific Reports</i> , <b>2019</b> , 9, 16324	4.9	63
468	Naltrexone differentially modulates the neural correlates of motor impulse control in abstinent alcohol-dependent and polysubstance-dependent individuals. <i>European Journal of Neuroscience</i> , <b>2019</b> , 50, 2311-2321	3.5	5
467	A new approach to formulating and appraising drug policy: A multi-criterion decision analysis applied to alcohol and cannabis regulation. <i>International Journal of Drug Policy</i> , <b>2018</b> , 56, 144-152	5.5	22
466	Natural speech algorithm applied to baseline interview data can predict which patients will respond to psilocybin for treatment-resistant depression. <i>Journal of Affective Disorders</i> , <b>2018</b> , 230, 84-86	6.6	16
465	The hidden therapist: evidence for a central role of music in psychedelic therapy. <i>Psychopharmacology</i> , <b>2018</b> , 235, 505-519	4.7	73
464	Psychiatry & the psychedelic drugs. Past, present & future. <i>Neuropharmacology</i> , <b>2018</b> , 142, 200-218	5.5	109
463	Increased amygdala responses to emotional faces after psilocybin for treatment-resistant depression. <i>Neuropharmacology</i> , <b>2018</b> , 142, 263-269	5.5	59

462	Evaluation of C-BU99008, a PET Ligand for the Imidazoline Binding Site in Human Brain. <i>Journal of Nuclear Medicine</i> , <b>2018</b> , 59, 1597-1602	8.9	38
461	Cerebral blood flow predicts differential neurotransmitter activity. <i>Scientific Reports</i> , <b>2018</b> , 8, 4074	4.9	27
460	Naltrexone ameliorates functional network abnormalities in alcohol-dependent individuals. <i>Addiction Biology</i> , <b>2018</b> , 23, 425-436	4.6	23
459	Psilocybin with psychological support improves emotional face recognition in treatment-resistant depression. <i>Psychopharmacology</i> , <b>2018</b> , 235, 459-466	4.7	35
458	Predicting Responses to Psychedelics: A Prospective Study. <i>Frontiers in Pharmacology</i> , <b>2018</b> , 9, 897	5.6	104
457	DMT Models the Near-Death Experience. <i>Frontiers in Psychology</i> , <b>2018</b> , 9, 1424	3.4	62
456	Cannabis and opioid overdoses: time to move on and examine potential mechanisms. <i>Addiction</i> , <b>2018</b> , 113, 1551-1552	4.6	6
455	Effects of psilocybin therapy on personality structure. <i>Acta Psychiatrica Scandinavica</i> , <b>2018</b> , 138, 368-378	6.5	85
454	Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. <i>Psychopharmacology</i> , <b>2018</b> , 235, 399-408	4.7	266
453	LSD modulates effective connectivity and neural adaptation mechanisms in an auditory oddball paradigm. <i>Neuropharmacology</i> , <b>2018</b> , 142, 251-262	5.5	22
452	First evaluation of PET-based human biodistribution and radiation dosimetry of C-BU99008, a tracer for imaging the imidazoline binding site. <i>EJNMMI Research</i> , <b>2018</b> , 8, 71	3.6	8
451	Using Baclofen to Explore GABA-B Receptor Function in Alcohol Dependence: Insights From Pharmacokinetic and Pharmacodynamic Measures. <i>Frontiers in Psychiatry</i> , <b>2018</b> , 9, 664	5	6
450	GABA receptor availability is not altered in adults with autism spectrum disorder or in mouse models. <i>Science Translational Medicine</i> , <b>2018</b> , 10,	17.5	26
449	Imaging and Genetic Approaches to Inform Biomarkers for Anxiety Disorders, Obsessive-Compulsive Disorders, and PTSD. <i>Current Topics in Behavioral Neurosciences</i> , <b>2018</b> , 40, 219-292	4	4
448	Psilocybin and MDMA reduce costly punishment in the Ultimatum Game. <i>Scientific Reports</i> , <b>2018</b> , 8, 8236	4.9	18
447	Nalmefene Reduces Reward Anticipation in Alcohol Dependence: An Experimental Functional Magnetic Resonance Imaging Study. <i>Biological Psychiatry</i> , <b>2017</b> , 81, 941-948	7.9	26
446	Toxicological evaluation of 5-methoxy-2-aminoindane (MEAI): Binge mitigating agent in development. <i>Toxicology and Applied Pharmacology</i> , <b>2017</b> , 319, 59-68	4.6	5
445	Altered Insula Connectivity under MDMA. <i>Neuropsychopharmacology</i> , <b>2017</b> , 42, 2152-2162	8.7	18

444	New ACMD regulations threaten UK's pharmaceutical discovery. <i>Lancet, The</i> , <b>2017</b> , 389, 2283	4.0	1
443	Concerns regarding conclusions made about LSD-treatments (received 25 October 2016). <i>History of Psychiatry</i> , <b>2017</b> , 28, 257-260	0.6	5
442	Patients' Accounts of Increased Connectedness and Acceptance After Psilocybin for Treatment-Resistant Depression. <i>Journal of Humanistic Psychology</i> , <b>2017</b> , 57, 520-564	0.9	154
441	Evidence for GABA-A receptor dysregulation in gambling disorder: correlation with impulsivity. <i>Addiction Biology</i> , <b>2017</b> , 22, 1601-1609	4.6	21
440	Acute D3 Antagonist GSK598809 Selectively Enhances Neural Response During Monetary Reward Anticipation in Drug and Alcohol Dependence. <i>Neuropsychopharmacology</i> , <b>2017</b> , 42, 1049-1057	8.7	20
439	Neural substrates of cue reactivity and craving in gambling disorder. <i>Translational Psychiatry</i> , <b>2017</b> , 7, e992	8.6	95
438	Inverse agonists - What do they mean for psychiatry?. <i>European Neuropsychopharmacology</i> , <b>2017</b> , 27, 87-90	1.2	10
437	A point mutation in the ion conduction pore of AMPA receptor GRIA3 causes dramatically perturbed sleep patterns as well as intellectual disability. <i>Human Molecular Genetics</i> , <b>2017</b> , 26, 3869-3882	5.6	24
436	Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms. <i>Scientific Reports</i> , <b>2017</b> , 7, 13187	4.9	192
435	Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression. <i>Frontiers in Pharmacology</i> , <b>2017</b> , 8, 974	5.6	242
434	Serotonin and brain function: a tale of two receptors. <i>Journal of Psychopharmacology</i> , <b>2017</b> , 31, 1091-1120	4.0	254
433	Effects of naltrexone are influenced by childhood adversity during negative emotional processing in addiction recovery. <i>Translational Psychiatry</i> , <b>2017</b> , 7, e1054	8.6	17
432	Tripping up addiction: the use of psychedelic drugs in the treatment of problematic drug and alcohol use. <i>Current Opinion in Behavioral Sciences</i> , <b>2017</b> , 13, 71-76	4	13
431	The ICCAM platform study: An experimental medicine platform for evaluating new drugs for relapse prevention in addiction. Part B: fMRI description. <i>Journal of Psychopharmacology</i> , <b>2017</b> , 31, 3-16	4.6	13
430	Acute naltrexone does not remediate fronto-striatal disturbances in alcoholic and alcohol polysubstance-dependent populations during a monetary incentive delay task. <i>Addiction Biology</i> , <b>2017</b> , 22, 1576-1589	4.6	15
429	Biological markers for anxiety disorders, OCD and PTSD: A consensus statement. Part II: Neurochemistry, neurophysiology and neurocognition. <i>World Journal of Biological Psychiatry</i> , <b>2017</b> , 18, 162-214	3.8	143
428	A multicenter positron emission tomography study of GABA receptor availability in adults with autism. <i>European Neuropsychopharmacology</i> , <b>2017</b> , 27, S716-S717	1.2	
427	An effective hangover treatment: Friend or Foe?. <i>Drug Science, Policy and Law</i> , <b>2017</b> , 3, 2050324517741038	3.8	14

426	Biological markers of generalized anxiety disorder. <i>Dialogues in Clinical Neuroscience</i> , <b>2017</b> , 19, 147-158	5.7	42
425	Acute and chronic effects of cannabinoids on effort-related decision-making and reward learning: an evaluation of the cannabis 'amotivational' hypotheses. <i>Psychopharmacology</i> , <b>2016</b> , 233, 3537-52	4.7	106
424	Semantic activation in LSD: evidence from picture naming. <i>Language, Cognition and Neuroscience</i> , <b>2016</b> , 31, 1320-1327	2.4	18
423	Biological markers for anxiety disorders, OCD and PTSD - a consensus statement. Part I: Neuroimaging and genetics. <i>World Journal of Biological Psychiatry</i> , <b>2016</b> , 17, 321-65	3.8	93
422	Don't panic. A guide to tryptophan depletion with disorder-specific anxiety provocation. <i>Journal of Psychopharmacology</i> , <b>2016</b> , 30, 1137-1140	4.6	2
421	Blunted Endogenous Opioid Release Following an Oral Amphetamine Challenge in Pathological Gamblers. <i>Neuropsychopharmacology</i> , <b>2016</b> , 41, 1742-50	8.7	83
420	In vivo imaging of microglial activation by positron emission tomography with [(11)C]PBR28 in the 5XFAD model of Alzheimer's disease. <i>Glia</i> , <b>2016</b> , 64, 993-1006	9	53
419	LSD-induced entropic brain activity predicts subsequent personality change. <i>Human Brain Mapping</i> , <b>2016</b> , 37, 3203-13	5.9	163
418	Effect of short-term escitalopram treatment on neural activation during emotional processing. <i>Journal of Psychopharmacology</i> , <b>2016</b> , 30, 33-9	4.6	7
417	Decreased mental time travel to the past correlates with default-mode network disintegration under lysergic acid diethylamide. <i>Journal of Psychopharmacology</i> , <b>2016</b> , 30, 344-53	4.6	93
416	Validated Method for the Quantification of Baclofen in Human Plasma Using Solid-Phase Extraction and Liquid Chromatography-Tandem Mass Spectrometry. <i>Journal of Analytical Toxicology</i> , <b>2016</b> , 40, 117-23	3.9	15
415	Ego-Dissolution and Psychedelics: Validation of the Ego-Dissolution Inventory (EDI). <i>Frontiers in Human Neuroscience</i> , <b>2016</b> , 10, 269	3.3	129
414	Behavioural tasks sensitive to acute abstinence and predictive of smoking cessation success: a systematic review and meta-analysis. <i>Addiction</i> , <b>2016</b> , 111, 2134-2144	4.6	12
413	LSD alters eyes-closed functional connectivity within the early visual cortex in a retinotopic fashion. <i>Human Brain Mapping</i> , <b>2016</b> , 37, 3031-40	5.9	29
412	E-cigarettes are less harmful than smoking. <i>Lancet, The</i> , <b>2016</b> , 387, 1160-2	4.0	32
411	Using [(11)C]Ro15 4513 PET to characterise GABA-benzodiazepine receptors in opiate addiction: Similarities and differences with alcoholism. <i>NeuroImage</i> , <b>2016</b> , 132, 1-7	7.9	7
410	Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. <i>Lancet Psychiatry, the</i> , <b>2016</b> , 3, 619-27	23.3	568
409	A pilot study of the effect of short-term escitalopram treatment on brain metabolites and gamma-oscillations in healthy subjects. <i>Journal of Psychopharmacology</i> , <b>2016</b> , 30, 579-80	4.6	3

408	A placebo-controlled investigation of synaesthesia-like experiences under LSD. <i>Neuropsychologia</i> , <b>2016</b> , 88, 28-34	3.2	29
407	Impulsivity in abstinent alcohol and polydrug dependence: a multidimensional approach. <i>Psychopharmacology</i> , <b>2016</b> , 233, 1487-99	4.7	21
406	Gamma-aminobutyric acid as a metabolite: Interpreting magnetic resonance spectroscopy experiments. <i>Journal of Psychopharmacology</i> , <b>2016</b> , 30, 422-7	4.6	9
405	Increased Global Functional Connectivity Correlates with LSD-Induced Ego Dissolution. <i>Current Biology</i> , <b>2016</b> , 26, 1043-50	6.3	237
404	LSD modulates music-induced imagery via changes in parahippocampal connectivity. <i>European Neuropsychopharmacology</i> , <b>2016</b> , 26, 1099-109	1.2	63
403	Neural correlates of the LSD experience revealed by multimodal neuroimaging. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2016</b> , 113, 4853-8	11.5	401
402	The paradoxical psychological effects of lysergic acid diethylamide (LSD). <i>Psychological Medicine</i> , <b>2016</b> , 46, 1379-90	6.9	156
401	Question-based Drug Development for psilocybin - Authors' reply. <i>Lancet Psychiatry</i> , <b>2016</b> , 3, 807	23.3	1
400	Whole-genome expression analysis reveals genes associated with treatment response to escitalopram in major depression. <i>European Neuropsychopharmacology</i> , <b>2016</b> , 26, 1475-1483	1.2	14
399	Significant reductions in human visual gamma frequency by the gaba reuptake inhibitor tiagabine revealed by robust peak frequency estimation. <i>Human Brain Mapping</i> , <b>2016</b> , 37, 3882-3896	5.9	22
398	Antidepressants and the adolescent brain. <i>Journal of Psychopharmacology</i> , <b>2015</b> , 29, 545-55	4.6	29
397	Evidence for serotonin function as a neurochemical difference between fear and anxiety disorders in humans?. <i>Journal of Psychopharmacology</i> , <b>2015</b> , 29, 1061-9	4.6	16
396	Illegal drugs laws: clearing a 50-year-old obstacle to research. <i>PLoS Biology</i> , <b>2015</b> , 13, e1002047	9.7	23
395	Progress in mind: focus on alcohol use disorders, an elsevier resource centre. <i>Psychiatry Research</i> , <b>2015</b> , 226, 513-4	9.9	6
394	European rating of drug harms. <i>Journal of Psychopharmacology</i> , <b>2015</b> , 29, 655-60	4.6	97
393	The dopamine theory of addiction: 40 years of highs and lows. <i>Nature Reviews Neuroscience</i> , <b>2015</b> , 16, 305-12	13.5	392
392	Psychopharmacological characterisation of the successive negative contrast effect in rats. <i>Psychopharmacology</i> , <b>2015</b> , 232, 2697-709	4.7	8
391	Distinct Neuropsychological Mechanisms May Explain Delayed- Versus Rapid-Onset Antidepressant Efficacy. <i>Neuropsychopharmacology</i> , <b>2015</b> , 40, 2165-74	8.7	41

390	Factors influencing success of clinical genome sequencing across a broad spectrum of disorders. <i>Nature Genetics</i> , <b>2015</b> , 47, 717-726	36.3	244
389	3-Methyl-methcathinone: Pharmacokinetic profile evaluation in pigs in relation to pharmacodynamics. <i>Journal of Psychopharmacology</i> , <b>2015</b> , 29, 734-43	4.6	16
388	Considerations on the role of buprenorphine in recovery from heroin addiction from a UK perspective. <i>Journal of Psychopharmacology</i> , <b>2015</b> , 29, 43-9	4.6	2
387	Neural correlates of change in major depressive disorder anhedonia following open-label ketamine. <i>Journal of Psychopharmacology</i> , <b>2015</b> , 29, 596-607	4.6	128
386	Ranking the harm of non-medically used prescription opioids in the UK. <i>Regulatory Toxicology and Pharmacology</i> , <b>2015</b> , 73, 999-1004	3.4	13
385	The Imperial College Cambridge Manchester (ICCAM) platform study: An experimental medicine platform for evaluating new drugs for relapse prevention in addiction. Part A: Study description. <i>Journal of Psychopharmacology</i> , <b>2015</b> , 29, 943-60	4.6	21
384	Mechanisms of Action and Persistent Neuroplasticity by Drugs of Abuse. <i>Pharmacological Reviews</i> , <b>2015</b> , 67, 872-1004	22.5	93
383	LSD enhances the emotional response to music. <i>Psychopharmacology</i> , <b>2015</b> , 232, 3607-14	4.7	83
382	Differentiated effects of the multimodal antidepressant vortioxetine on sleep architecture: Part 1, a pharmacokinetic/pharmacodynamic comparison with paroxetine in healthy men. <i>Journal of Psychopharmacology</i> , <b>2015</b> , 29, 1085-91	4.6	17
381	A review of the current nomenclature for psychotropic agents and an introduction to the Neuroscience-based Nomenclature. <i>European Neuropsychopharmacology</i> , <b>2015</b> , 25, 2318-25	1.2	89
380	The European College of Neuropsychopharmacology (ECNP) Medicines Chest Initiative: Rationale and Promise. <i>Pharmaceutical Medicine</i> , <b>2015</b> , 29, 269-273	2.3	1
379	Differences between magnetoencephalographic (MEG) spectral profiles of drugs acting on GABA at synaptic and extrasynaptic sites: a study in healthy volunteers. <i>Neuropharmacology</i> , <b>2015</b> , 88, 155-63	5.5	25
378	The Effects of Acutely Administered 3,4-Methylenedioxymethamphetamine on Spontaneous Brain Function in Healthy Volunteers Measured with Arterial Spin Labeling and Blood Oxygen Level-Dependent Resting State Functional Connectivity. <i>Biological Psychiatry</i> , <b>2015</b> , 78, 554-62	7.9	96
377	Antidepressant drug development: Focus on triple monoamine reuptake inhibition. <i>Journal of Psychopharmacology</i> , <b>2015</b> , 29, 526-44	4.6	27
376	LSD enhances suggestibility in healthy volunteers. <i>Psychopharmacology</i> , <b>2015</b> , 232, 785-94	4.7	127
375	Assessment of the quality of brain regions and neuroimaging metrics as biomarkers of Alzheimer's Disease. <i>EJNMMI Physics</i> , <b>2015</b> , 2, A46	4.4	
374	Optimising PET approaches to measuring 5-HT release in human brain. <i>Synapse</i> , <b>2015</b> , 69, 505-11	2.4	13
373	Influence of agonist induced internalization on [3H]Ro15-4513 binding-an application to imaging fluctuations in endogenous GABA with positron emission tomography. <i>Synapse</i> , <b>2015</b> , 69, 60-5	2.4	8

372	Finding the self by losing the self: Neural correlates of ego-dissolution under psilocybin. <i>Human Brain Mapping</i> , <b>2015</b> , 36, 3137-53	5.9	122
371	Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2008 British Association for Psychopharmacology guidelines. <i>Journal of Psychopharmacology</i> , <b>2015</b> , 29, 459-525	4.6	381
370	A Lifetime Prevalence of Comorbidity Between Bipolar Affective Disorder and Anxiety Disorders: A Meta-analysis of 52 Interview-based Studies of Psychiatric Population. <i>EBioMedicine</i> , <b>2015</b> , 2, 1405-19	8.8	56
369	Harmane: an atypical neurotransmitter?. <i>Neuroscience Letters</i> , <b>2015</b> , 590, 1-5	3.3	8
368	Biological predictors of pharmacological therapy in anxiety disorders. <i>Dialogues in Clinical Neuroscience</i> , <b>2015</b> , 17, 305-17	5.7	16
367	Pharmacology should be at the centre of all preclinical and clinical studies on new psychoactive substances (recreational drugs). <i>Journal of Psychopharmacology</i> , <b>2014</b> , 28, 711-8	4.6	13
366	Adverse effects from antidepressant treatment: randomised controlled trial of 601 depressed individuals. <i>Psychopharmacology</i> , <b>2014</b> , 231, 2921-31	4.7	45
365	Doing it by numbers: a simple approach to reducing the harms of alcohol. <i>Journal of Psychopharmacology</i> , <b>2014</b> , 28, 3-7	4.6	52
364	The role of the opioid system in alcohol dependence. <i>Journal of Psychopharmacology</i> , <b>2014</b> , 28, 8-22	4.6	53
363	Stratified medicine for mental disorders. <i>European Neuropsychopharmacology</i> , <b>2014</b> , 24, 5-50	1.2	121
362	CNS drug development in Europe--past progress and future challenges. <i>Neurobiology of Disease</i> , <b>2014</b> , 61, 6-20	7.5	26
361	Homological scaffolds of brain functional networks. <i>Journal of the Royal Society Interface</i> , <b>2014</b> , 11, 20140873	4.73	269
360	P.6.f.002 Endogenous opioid release in pathological gamblers after an oral amphetamine challenge: a [ <sup>11</sup> C]carfentanil PET study. <i>European Neuropsychopharmacology</i> , <b>2014</b> , 24, S699-S700	1.2	1
359	Evaluation of <sup>11</sup> C-BU99008, a PET ligand for the imidazoline <sub>2</sub> binding sites in rhesus brain. <i>Journal of Nuclear Medicine</i> , <b>2014</b> , 55, 838-44	8.9	35
358	Attacks on antidepressants: signs of deep-seated stigma?. <i>Lancet Psychiatry</i> , <b>2014</b> , 1, 102-4	23.3	21
357	Enhanced repertoire of brain dynamical states during the psychedelic experience. <i>Human Brain Mapping</i> , <b>2014</b> , 35, 5442-56	5.9	211
356	Lamotrigine for attention deficit-hyperactivity disorder comorbid with mood disorders: a case series. <i>Journal of Psychopharmacology</i> , <b>2014</b> , 28, 282-3	4.6	9
355	Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology. <i>Journal of Psychopharmacology</i> , <b>2014</b> , 28, 403-39	4.6	387

354	Recommended diagnosis and management of insomnia. <i>The Prescriber</i> , <b>2014</b> , 25, 12-20	0.4	1
353	Evidence-based guidelines for the pharmacological management of attention deficit hyperactivity disorder: update on recommendations from the British Association for Psychopharmacology. <i>Journal of Psychopharmacology</i> , <b>2014</b> , 28, 179-203	4.6	191
352	Acute increases in synaptic GABA detectable in the living human brain: a [ <sup>11</sup> C]Ro15-4513 PET study. <i>NeuroImage</i> , <b>2014</b> , 99, 158-65	7.9	37
351	Where now for schizophrenia research?. <i>European Neuropsychopharmacology</i> , <b>2014</b> , 24, 1181-7	1.2	9
350	The influence of different cellular environments on PET radioligand binding: an application to D2/3-dopamine receptor imaging. <i>Neuropharmacology</i> , <b>2014</b> , 85, 305-13	5.5	12
349	Deaths from "legal highs": a problem of definitions. <i>Lancet, The</i> , <b>2014</b> , 383, 952	4.0	20
348	The effects of psilocybin and MDMA on between-network resting state functional connectivity in healthy volunteers. <i>Frontiers in Human Neuroscience</i> , <b>2014</b> , 8, 204	3.3	128
347	8. Neurobiologie des troubles anxieux <b>2014</b> , 69		0
346	The entropic brain: a theory of conscious states informed by neuroimaging research with psychedelic drugs. <i>Frontiers in Human Neuroscience</i> , <b>2014</b> , 8, 20	3.3	409
345	The effect of acutely administered MDMA on subjective and BOLD-fMRI responses to favourite and worst autobiographical memories. <i>International Journal of Neuropsychopharmacology</i> , <b>2014</b> , 17, 527-40	5.8	50
344	Determination of [(11)C]PBR28 binding potential in vivo: a first human TSPO blocking study. <i>Journal of Cerebral Blood Flow and Metabolism</i> , <b>2014</b> , 34, 989-94	7.3	98
343	In vivo imaging of cerebral dopamine D3 receptors in alcoholism. <i>Neuropsychopharmacology</i> , <b>2014</b> , 39, 1703-12	8.7	48
342	Imaging endogenous opioid peptide release with [ <sup>11</sup> C]carfentanil and [ <sup>3</sup> H]diprenorphine: influence of agonist-induced internalization. <i>Journal of Cerebral Blood Flow and Metabolism</i> , <b>2014</b> , 34, 1604-12	7.3	27
341	A randomised trial of the effect of the glycine reuptake inhibitor Org 25935 on cognitive performance in healthy male volunteers. <i>Human Psychopharmacology</i> , <b>2014</b> , 29, 163-71	2.3	4
340	Mind-altering drugs and research: from presumptive prejudice to a Neuroscientific Enlightenment?: Science & Society series on "Drugs and Science". <i>EMBO Reports</i> , <b>2014</b> , 15, 208-11	6.5	11
339	The Hamilton Depression Scale--accelerator or break on antidepressant drug discovery?. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2014</b> , 85, 119-20	5.5	16
338	Allowing for non-adherence to treatment in a randomized controlled trial of two antidepressants (citalopram versus reboxetine): an example from the GENPOD trial. <i>Psychological Medicine</i> , <b>2014</b> , 44, 2855-66	6.9	10
337	Estimating the harms of nicotine-containing products using the MCDA approach. <i>European Addiction Research</i> , <b>2014</b> , 20, 218-25	4.6	235

336	Investigating expectation and reward in human opioid addiction with [(11) C]raclopride PET. <i>Addiction Biology</i> , <b>2014</b> , 19, 1032-40	4.6	19
335	Amphetamine induced endogenous opioid release in the human brain detected with [(11)C]carfentanil PET: replication in an independent cohort. <i>International Journal of Neuropsychopharmacology</i> , <b>2014</b> , 17, 2069-74	5.8	71
334	Are multiple physical symptoms a poor prognostic factor or just a marker of depression severity? Secondary analysis of the GenPod trial. <i>Journal of Affective Disorders</i> , <b>2014</b> , 163, 40-6	6.6	1
333	A proposal for an updated neuropsychopharmacological nomenclature. <i>European Neuropsychopharmacology</i> , <b>2014</b> , 24, 1005-14	1.2	60
332	Was it a vision or a waking dream?. <i>Frontiers in Psychology</i> , <b>2014</b> , 5, 255	3.4	20
331	5-HT radioligands for human brain imaging with PET and SPECT. <i>Medicinal Research Reviews</i> , <b>2013</b> , 33, 54-111	14.4	111
330	Addiction: lifestyle choice or medical diagnosis?. <i>Journal of Evaluation in Clinical Practice</i> , <b>2013</b> , 19, 493-62.5		4
329	A translational rodent assay of affective biases in depression and antidepressant therapy. <i>Neuropsychopharmacology</i> , <b>2013</b> , 38, 1625-35	8.7	67
328	Psychiatry's next top model: cause for a re-think on drug models of psychosis and other psychiatric disorders. <i>Journal of Psychopharmacology</i> , <b>2013</b> , 27, 771-8	4.6	31
327	Innovative solutions to novel drug development in mental health. <i>Neuroscience and Biobehavioral Reviews</i> , <b>2013</b> , 37, 2438-44	9	75
326	Benzodiazepines: risks and benefits. A reconsideration. <i>Journal of Psychopharmacology</i> , <b>2013</b> , 27, 967-71	4.6	130
325	Broadband cortical desynchronization underlies the human psychedelic state. <i>Journal of Neuroscience</i> , <b>2013</b> , 33, 15171-83	6.6	258
324	Resting state synchrony in anxiety-related circuits of abstinent alcohol-dependent patients. <i>American Journal of Drug and Alcohol Abuse</i> , <b>2013</b> , 39, 433-40	3.7	9
323	Amphetamine, past and present--a pharmacological and clinical perspective. <i>Journal of Psychopharmacology</i> , <b>2013</b> , 27, 479-96	4.6	300
322	History of cigarette smoking is associated with higher limbic GABAA receptor availability. <i>NeuroImage</i> , <b>2013</b> , 69, 70-7	7.9	17
321	Defining substance use disorders: do we really need more than heavy use?. <i>Alcohol and Alcoholism</i> , <b>2013</b> , 48, 633-40	3.5	155
320	The effect of 6-week treatment with escitalopram on CCK-4 challenge: a placebo-controlled study in CCK-4-sensitive healthy volunteers. <i>European Neuropsychopharmacology</i> , <b>2013</b> , 23, 645-52	1.2	6
319	Generic legislation of new psychoactive drugs. <i>Journal of Psychopharmacology</i> , <b>2013</b> , 27, 317-24	4.6	44

318	The brain GABA-benzodiazepine receptor alpha-5 subtype in autism spectrum disorder: a pilot [(11C)Ro15-4513 positron emission tomography study. <i>Neuropharmacology</i> , <b>2013</b> , 68, 195-201	5.5	79
317	Effects of Schedule I drug laws on neuroscience research and treatment innovation. <i>Nature Reviews Neuroscience</i> , <b>2013</b> , 14, 577-85	13.5	178
316	The effects of elevated endogenous GABA levels on movement-related network oscillations. <i>NeuroImage</i> , <b>2013</b> , 66, 36-41	7.9	108
315	Functional connectivity measures after psilocybin inform a novel hypothesis of early psychosis. <i>Schizophrenia Bulletin</i> , <b>2013</b> , 39, 1343-51	1.3	148
314	The size, burden and cost of disorders of the brain in the UK. <i>Journal of Psychopharmacology</i> , <b>2013</b> , 27, 761-70	4.6	109
313	Stratified medicine in psychiatry: a worrying example or new opportunity in the treatment of anxiety?. <i>Journal of Psychopharmacology</i> , <b>2013</b> , 27, 119-22	4.6	14
312	Imaging imidazoline-I2 binding sites in porcine brain using 11C-BU99008. <i>Journal of Nuclear Medicine</i> , <b>2013</b> , 54, 139-44	8.9	25
311	Evaluation of the effects of venlafaxine and pregabalin on the carbon dioxide inhalation models of Generalised Anxiety Disorder and panic. <i>Journal of Psychopharmacology</i> , <b>2013</b> , 27, 135-45	4.6	10
310	Changes in cardiovascular function after venlafaxine but not pregabalin in healthy volunteers: a double-blind, placebo-controlled study of orthostatic challenge, blood pressure and heart rate. <i>Human Psychopharmacology</i> , <b>2013</b> , 28, 562-75	2.3	10
309	Anhedonia revisited: is there a role for dopamine-targeting drugs for depression?. <i>Journal of Psychopharmacology</i> , <b>2013</b> , 27, 869-77	4.6	77
308	New victims of current drug laws. <i>Nature Reviews Neuroscience</i> , <b>2013</b> , 14, 877	13.5	7
307	Whole-exome sequencing identifies a polymorphism in the BMP5 gene associated with SSRI treatment response in major depression. <i>Journal of Psychopharmacology</i> , <b>2013</b> , 27, 915-20	4.6	24
306	Opiate agonists and antagonists modulate taste perception in opiate-maintained and recently detoxified subjects. <i>Journal of Psychopharmacology</i> , <b>2013</b> , 27, 265-75	4.6	17
305	Elevating endogenous GABA levels with GAT-1 blockade modulates evoked but not induced responses in human visual cortex. <i>Neuropsychopharmacology</i> , <b>2013</b> , 38, 1105-12	8.7	30
304	Effects of 7.5% CO2-Induced Anxiety on Individual Performance During a Group Computer Combat Game. <i>Military Psychology</i> , <b>2013</b> , 25, 615-622	0.9	4
303	Can Neuroscience Improve Addiction Treatment and Policies?. <i>Public Health Reviews</i> , <b>2013</b> , 35,	4.3	2
302	Personalized risk assessment of drug-related harm is associated with health outcomes. <i>PLoS ONE</i> , <b>2013</b> , 8, e79754	3.7	8
301	Opioids Neuroimaging <b>2013</b> , 675-687		1

300	The effect of a clinically effective and non-effective dose of lorazepam on 7.5% CO <sub>2</sub> induced anxiety. <i>Human Psychopharmacology</i> , <b>2012</b> , 27, 540-8	2.3	8
299	Massive overuse or appropriate medical intervention? The modern-day use of antidepressants. <i>Current Opinion in Pharmacology</i> , <b>2012</b> , 12, 109-10	5.1	3
298	GABA system dysfunction in autism and related disorders: from synapse to symptoms. <i>Neuroscience and Biobehavioral Reviews</i> , <b>2012</b> , 36, 2044-55	9	268
297	Elucidation of neurobiology of anxiety disorders in children through pharmacological challenge tests and cortisol measurements: a systematic review. <i>Journal of Psychopharmacology</i> , <b>2012</b> , 26, 431-42	4.6	11
296	BAP updated guidelines: evidence-based guidelines for the pharmacological management of substance abuse, harmful use, addiction and comorbidity: recommendations from BAP. <i>Journal of Psychopharmacology</i> , <b>2012</b> , 26, 899-952	4.6	204
295	The hidden third: improving outcome in treatment-resistant depression. <i>Journal of Psychopharmacology</i> , <b>2012</b> , 26, 587-602	4.6	49
294	Influence of different cellular environments on [(3)H]DASB radioligand binding. <i>Synapse</i> , <b>2012</b> , 66, 1035-44	2.4	17
293	Evaluation of an operant successive negative contrast task as a method to study affective state in rodents. <i>Behavioural Brain Research</i> , <b>2012</b> , 234, 155-60	3.4	19
292	Endogenous opioid release in the human brain reward system induced by acute amphetamine administration. <i>Biological Psychiatry</i> , <b>2012</b> , 72, 371-7	7.9	82
291	Striatal dopamine D <sub>1</sub> receptor binding in pathological gambling is correlated with mood-related impulsivity. <i>NeuroImage</i> , <b>2012</b> , 63, 40-6	7.9	156
290	Anxiolytics. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , <b>2012</b> , 106, 669-79	3	1
289	Drug research: a plan for mental illness. <i>Nature</i> , <b>2012</b> , 483, 269	50.4	53
288	Brain Imaging in Addiction <b>2012</b> , 3-25		1
287	Evaluation and initial in vitro and ex vivo characterization of the potential positron emission tomography ligand, BU99008 (2-(4,5-dihydro-1H-imidazol-2-yl)-1-methyl-1H-indole), for the imidazoline binding site. <i>Synapse</i> , <b>2012</b> , 66, 542-51	2.4	33
286	Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2012</b> , 109, 2138-43	11.5	555
285	Implications for psychedelic-assisted psychotherapy: functional magnetic resonance imaging study with psilocybin. <i>British Journal of Psychiatry</i> , <b>2012</b> , 200, 238-44	5.4	122
284	The effects of 7.5% carbon dioxide inhalation on task performance in healthy volunteers. <i>Journal of Psychopharmacology</i> , <b>2012</b> , 26, 487-96	4.6	11
283	Severity of depression and response to antidepressants: GENPOD randomised controlled trial. <i>British Journal of Psychiatry</i> , <b>2012</b> , 200, 130-6	5.4	18

282	Popular intoxicants: what lessons can be learned from the last 40 years of alcohol and cannabis regulation?. <i>Journal of Psychopharmacology</i> , <b>2012</b> , 26, 213-20	4.6	11
281	Does baseline fatigue influence treatment response to reboxetine or citalopram in depression? An open label randomized controlled trial. <i>Journal of Psychopharmacology</i> , <b>2012</b> , 26, 663-9	4.6	5
280	A [ <sup>11</sup> C]Ro15 4513 PET study suggests that alcohol dependence in man is associated with reduced $\alpha$ benzodiazepine receptors in limbic regions. <i>Journal of Psychopharmacology</i> , <b>2012</b> , 26, 273-81	4.6	39
279	Characterisation of the contribution of the GABA-benzodiazepine $\alpha$ receptor subtype to [(11)C]Ro15-4513 PET images. <i>Journal of Cerebral Blood Flow and Metabolism</i> , <b>2012</b> , 32, 731-44	7.3	24
278	Substitution therapy for alcoholism: time for a reappraisal?. <i>Journal of Psychopharmacology</i> , <b>2012</b> , 26, 205-12	4.6	53
277	History of cannabis use is not associated with alterations in striatal dopamine D2/D3 receptor availability. <i>Journal of Psychopharmacology</i> , <b>2012</b> , 26, 144-9	4.6	49
276	A U-shaped relationship between systolic blood pressure and panic symptoms: the HUNT study. <i>Psychological Medicine</i> , <b>2012</b> , 42, 1969-76	6.9	9
275	Author's reply: Suppressing addiction using high-dose baclofen, rather than using substitution therapy. <i>Journal of Psychopharmacology</i> , <b>2012</b> , 26, 1044-1044	4.6	
274	Neuroimaging of serotonin system in anxiety disorders. <i>Current Pharmaceutical Design</i> , <b>2012</b> , 18, 5699-708	9.8	26
273	A web-based survey on mephedrone. <i>Drug and Alcohol Dependence</i> , <b>2011</b> , 118, 19-22	4.9	200
272	Effects of 7.5% CO <sub>2</sub> challenge in generalized anxiety disorder. <i>Journal of Psychopharmacology</i> , <b>2011</b> , 25, 43-51	4.6	27
271	Perverse effects of the precautionary principle: how banning mephedrone has unexpected implications for pharmaceutical discovery. <i>Therapeutic Advances in Psychopharmacology</i> , <b>2011</b> , 1, 35-6	4.9	13
270	Noradrenergic function in generalized anxiety disorder: impact of treatment with venlafaxine on the physiological and psychological responses to clonidine challenge. <i>Journal of Psychopharmacology</i> , <b>2011</b> , 25, 78-86	4.6	20
269	GABAergic control of novelty stress-responsive epigenetic and gene expression mechanisms in the rat dentate gyrus. <i>European Neuropsychopharmacology</i> , <b>2011</b> , 21, 316-24	1.2	24
268	Polymorphism of the 5-HT transporter and response to antidepressants: randomised controlled trial. <i>British Journal of Psychiatry</i> , <b>2011</b> , 198, 464-71	5.4	51
267	Let not the best be the enemy of the good. <i>Addiction</i> , <b>2011</b> , 106, 1892-3; discussion 1896-8	4.6	5
266	Neuroscience in recession?. <i>Nature Reviews Neuroscience</i> , <b>2011</b> , 12, 297-302	13.5	11
265	Rapid tryptophan depletion following cognitive behavioural therapy for panic disorder. <i>Psychopharmacology</i> , <b>2011</b> , 213, 593-602	4.7	6

264	A pilot study of the effectiveness of D-cycloserine during cue-exposure therapy in abstinent alcohol-dependent subjects. <i>Psychopharmacology</i> , <b>2011</b> , 216, 121-9	4.7	29
263	Variation in binding affinity of the novel anxiolytic XBD173 for the 18 kDa translocator protein in human brain. <i>Synapse</i> , <b>2011</b> , 65, 257-9	2.4	33
262	Effects of 7.5% CO(2) inhalation on allocation of spatial attention to facial cues of emotional expression. <i>Cognition and Emotion</i> , <b>2011</b> , 25, 626-38	2.3	17
261	The administration of psilocybin to healthy, hallucinogen-experienced volunteers in a mock-functional magnetic resonance imaging environment: a preliminary investigation of tolerability. <i>Journal of Psychopharmacology</i> , <b>2011</b> , 25, 1562-7	4.6	33
260	Preliminary evidence of anxiolytic effects of the CRF(1) receptor antagonist R317573 in the 7.5% CO(2) proof-of-concept experimental model of human anxiety. <i>Journal of Psychopharmacology</i> , <b>2011</b> , 25, 1199-206	4.6	47
259	Gender differences in brain serotonin transporter availability in panic disorder. <i>Journal of Psychopharmacology</i> , <b>2011</b> , 25, 952-9	4.6	36
258	Sleep and its disorders in translational medicine. <i>Journal of Psychopharmacology</i> , <b>2011</b> , 25, 1226-34	4.6	19
257	Validating the inhalation of 7.5% CO(2) in healthy volunteers as a human experimental medicine: a model of generalized anxiety disorder (GAD). <i>Journal of Psychopharmacology</i> , <b>2011</b> , 25, 1192-8	4.6	30
256	Opioids and anxiety. <i>Journal of Psychopharmacology</i> , <b>2011</b> , 25, 1415-33	4.6	72
255	Highlights of the international consensus statement on major depressive disorder. <i>Journal of Clinical Psychiatry</i> , <b>2011</b> , 72, e21	4.6	9
254	Science and non-science in UK drug policy. <i>Addiction</i> , <b>2010</b> , 105, 1154	4.6	4
253	Measuring endogenous 5-HT release by emission tomography: promises and pitfalls. <i>Journal of Cerebral Blood Flow and Metabolism</i> , <b>2010</b> , 30, 1682-706	7.3	115
252	The physical health challenges in patients with severe mental illness: cardiovascular and metabolic risks. <i>Journal of Psychopharmacology</i> , <b>2010</b> , 24, 1-8	4.6	10
251	What one hand giveth the other taketh away: some unpredicted effects of enantiomers in psychopharmacology. <i>Journal of Psychopharmacology</i> , <b>2010</b> , 24, 1137-41	4.6	10
250	GABAB receptors in addiction and its treatment. <i>Advances in Pharmacology</i> , <b>2010</b> , 58, 373-96	5.7	71
249	Antagonist-agonist combinations as therapies for heroin addiction: back to the future?. <i>Journal of Psychopharmacology</i> , <b>2010</b> , 24, 141-5	4.6	4
248	The effects of single dose anxiolytic medication on the CO2 models of anxiety: differentiation of subjective and objective measures. <i>Journal of Psychopharmacology</i> , <b>2010</b> , 24, 649-56	4.6	21
247	Anxiety--bridging the heart/mind divide. <i>Journal of Psychopharmacology</i> , <b>2010</b> , 24, 633-8	4.6	17

246	Microbial infections in eight genomic subtypes of chronic fatigue syndrome/myalgic encephalomyelitis. <i>Journal of Clinical Pathology</i> , <b>2010</b> , 63, 156-64	3.9	59
245	Significant decreases in frontal and temporal [ <sup>11</sup> C]-raclopride binding after THC challenge. <i>NeuroImage</i> , <b>2010</b> , 52, 1521-7	7.9	63
244	British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders. <i>Journal of Psychopharmacology</i> , <b>2010</b> , 24, 1577-601 <sup>f</sup>	6.1 <sup>f</sup>	365
243	Increased serum free tryptophan in patients with diarrhea-predominant irritable bowel syndrome. <i>Nutrition Research</i> , <b>2010</b> , 30, 678-88	4	27
242	Voluntary exercise alters GABA(A) receptor subunit and glutamic acid decarboxylase-67 gene expression in the rat forebrain. <i>Journal of Psychopharmacology</i> , <b>2010</b> , 24, 745-56	4.6	43
241	Nutt damage [Author's reply]. <i>Lancet, The</i> , <b>2010</b> , 375, 724	4.0	1
240	Vienna Declaration: a call for evidence-based drug policies. <i>Lancet, The</i> , <b>2010</b> , 376, 310-2	4.0	76
239	Drug harms in the UK: a multicriteria decision analysis. <i>Lancet, The</i> , <b>2010</b> , 376, 1558-65	4.0	908
238	Harms associated with psychoactive substances: findings of the UK National Drug Survey. <i>Journal of Psychopharmacology</i> , <b>2010</b> , 24, 147-53	4.6	47
237	The role and basis of the drug laws. <i>Prometheus</i> , <b>2010</b> , 28, 293-297	0	2
236	Searching for perfect sleep: the continuing evolution of GABAA receptor modulators as hypnotics. <i>Journal of Psychopharmacology</i> , <b>2010</b> , 24, 1601-12	4.6	110
235	User perceptions of the benefits and harms of hallucinogenic drug use: A web-based questionnaire study. <i>Journal of Substance Use</i> , <b>2010</b> , 15, 283-300	0.8	37
234	The pharmacology of anxiety. <i>Current Topics in Behavioral Neurosciences</i> , <b>2010</b> , 2, 303-30	3.4	46
233	Effects of acute tryptophan depletion in serotonin reuptake inhibitor-remitted patients with generalized anxiety disorder. <i>Psychopharmacology</i> , <b>2010</b> , 208, 223-32	4.7	15
232	Dopamine transporter binding in females with panic disorder may vary with clinical status. <i>Journal of Psychiatric Research</i> , <b>2010</b> , 44, 56-9	5.2	16
231	Rationale for, barriers to, and appropriate medication for the long-term treatment of depression. <i>Journal of Clinical Psychiatry</i> , <b>2010</b> , 71 Suppl E1, e02	4.6	10
230	International consensus statement on major depressive disorder. <i>Journal of Clinical Psychiatry</i> , <b>2010</b> , 71 Suppl E1, e08	4.6	26
229	Current and former ecstasy users report different sleep to matched controls: a web-based questionnaire study. <i>Journal of Psychopharmacology</i> , <b>2009</b> , 23, 249-57	4.6	17

228	A comparison of the effects of a subtype selective and non-selective benzodiazepine receptor agonist in two CO(2) models of experimental human anxiety. <i>Journal of Psychopharmacology</i> , <b>2009</b> , 23, 117-22	4.6	35
227	That warm fuzzy feeling: brain serotonergic neurons and the regulation of emotion. <i>Journal of Psychopharmacology</i> , <b>2009</b> , 23, 392-400	4.6	64
226	Identification of an imidazoline binding protein: creatine kinase and an imidazoline-2 binding site. <i>Brain Research</i> , <b>2009</b> , 1279, 21-8	3.7	29
225	Emotional symptoms in children: The effect of maternal depression, life events, and COMT genotype. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , <b>2009</b> , 150B, 209-18	3.5	19
224	Effects of stressful life events, maternal depression and 5-HTTLPR genotype on emotional symptoms in pre-adolescent children. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , <b>2009</b> , 150B, 670-82	3.5	50
223	Cardiac slowing and acute tryptophan depletion: a comment on the paper by van der Veen et al. <i>Psychopharmacology</i> , <b>2009</b> , 203, 831-3; author reply 835-6	4.7	1
222	Equivalent effects of acute tryptophan depletion on REM sleep in ecstasy users and controls. <i>Psychopharmacology</i> , <b>2009</b> , 206, 187-96	4.7	12
221	Redistribution of slow wave activity of sleep during pharmacological treatment of depression with paroxetine but not with nefazodone. <i>Journal of Sleep Research</i> , <b>2009</b> , 18, 342-8	5.8	10
220	Characterisation of the effects of caffeine on sleep in the rat: a potential model of sleep disruption. <i>Journal of Psychopharmacology</i> , <b>2009</b> , 23, 475-86	4.6	24
219	Serotonin and sensitivity to trauma-related exposure in selective serotonin reuptake inhibitors-recovered posttraumatic stress disorder. <i>Biological Psychiatry</i> , <b>2009</b> , 66, 17-24	7.9	36
218	Introducing the Pharmacology Behind Treatments to Understand Treatment Challenges. <i>European Psychiatry</i> , <b>2009</b> , 24, 1-1	6	
217	Effects on sleep stages and microarchitecture of caffeine and its combination with zolpidem or trazodone in healthy volunteers. <i>Journal of Psychopharmacology</i> , <b>2009</b> , 23, 487-94	4.6	21
216	Antidepressant-induced jitteriness/anxiety syndrome: systematic review. <i>British Journal of Psychiatry</i> , <b>2009</b> , 194, 483-90	5.4	123
215	Serotonin transporter promoter region polymorphisms do not influence treatment response to escitalopram in patients with major depression. <i>European Neuropsychopharmacology</i> , <b>2009</b> , 19, 451-6	1.2	51
214	Brain opioid receptor binding in early abstinence from alcohol dependence and relationship to craving: an [ <sup>11</sup> C]diprenorphine PET study. <i>European Neuropsychopharmacology</i> , <b>2009</b> , 19, 740-8	1.2	58
213	Government vs science over drug and alcohol policy. <i>Lancet, The</i> , <b>2009</b> , 374, 1731-3	4.0	11
212	Women with diarrhoea-predominant irritable bowel syndrome show an increased pressure response to 35% carbon dioxide stress challenge. <i>Stress</i> , <b>2009</b> , 12, 30-6	3	7
211	Addiction: the clinical interface. <i>British Journal of Pharmacology</i> , <b>2008</b> , 154, 397-405	8.6	34

210	Does alcohol increase the risk of overdose death: the need for a translational approach. <i>Addiction</i> , <b>2008</b> , 103, 1060-2	4.6	43
209	UNDERSTANDING CAUSAL PATHWAYS: A RESPONSE TO THE COMMENTARIES. <i>Addiction</i> , <b>2008</b> , 103, 1067-1068	4.6	2
208	Is the association of hypertension and panic disorder explained by clustering of autonomic panic symptoms in hypertensive patients?. <i>Journal of Affective Disorders</i> , <b>2008</b> , 111, 344-50	6.6	6
207	GABA-A receptors and the response to CO(2) inhalation - a translational trans-species model of anxiety?. <i>Pharmacology Biochemistry and Behavior</i> , <b>2008</b> , 90, 51-7	3.9	21
206	Chapter 5.1 Phenomenology of anxiety disorders. <i>Handbook of Behavioral Neuroscience</i> , <b>2008</b> , 365-393	0.7	6
205	Reduced thalamic grey matter volume in opioid dependence is influenced by degree of alcohol use: a voxel-based morphometry study. <i>Journal of Psychopharmacology</i> , <b>2008</b> , 22, 7-10	4.6	27
204	Assessment of GABAA benzodiazepine receptor (GBzR) sensitivity in patients with alcohol dependence. <i>Alcohol and Alcoholism</i> , <b>2008</b> , 43, 614-8	3.5	6
203	Reply to letter by Green, Marsden and Fone (2007) about Sessa and Nutt's editorial (MDMA: baby with the bath water) in the November 2007 journal. <i>Journal of Psychopharmacology</i> , <b>2008</b> , 22, 457-8	4.6	3
202	Reply to OCD letter. <i>Journal of Psychopharmacology</i> , <b>2008</b> , 22, 338	4.6	1
201	Gene expression subtypes in patients with chronic fatigue syndrome/myalgic encephalomyelitis. <i>Journal of Infectious Diseases</i> , <b>2008</b> , 197, 1171-84	7	91
200	Introduction. The neurobiology of drug addiction: new vistas. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , <b>2008</b> , 363, 3109-11	5.8	12
199	Establishing non-inferiority in treatment trials in psychiatry: guidelines from an Expert Consensus Meeting. <i>Journal of Psychopharmacology</i> , <b>2008</b> , 22, 409-16	4.6	21
198	Serotonin 5-HT1A receptor binding in people with panic disorder: positron emission tomography study. <i>British Journal of Psychiatry</i> , <b>2008</b> , 193, 229-34	5.4	147
197	Brain dopamine response in human opioid addiction. <i>British Journal of Psychiatry</i> , <b>2008</b> , 193, 65-72	5.4	53
196	Potential novel anxiolytic drugs. <i>Current Pharmaceutical Design</i> , <b>2008</b> , 14, 3534-46	3.3	30
195	Tryptophan research in panic disorder. <i>International Journal of Tryptophan Research</i> , <b>2008</b> , 1, 3-12	5.6	2
194	Effects of acute tyrosine/phenylalanine depletion on the selective processing of smoking-related cues and the relative value of cigarettes in smokers. <i>Psychopharmacology</i> , <b>2008</b> , 196, 611-21	4.7	48
193	Mourning and melancholia revisited: correspondences between principles of Freudian metapsychology and empirical findings in neuropsychiatry. <i>Annals of General Psychiatry</i> , <b>2008</b> , 7, 9	3.4	68

192	GENetic and clinical predictors of treatment response in depression: the GenPod randomised trial protocol. <i>Trials</i> , <b>2008</b> , 9, 29	2.8	20
191	Brain opioid receptor binding in early abstinence from opioid dependence: positron emission tomography study. <i>British Journal of Psychiatry</i> , <b>2007</b> , 191, 63-9	5.4	58
190	Role of GABA in anxiety and depression. <i>Depression and Anxiety</i> , <b>2007</b> , 24, 495-517	8.4	335
189	The effect of nicotine on striatal dopamine release in man: A [ <sup>11</sup> C]raclopride PET study. <i>Synapse</i> , <b>2007</b> , 61, 637-45	2.4	79
188	Pharmacological treatment of bipolar disorder. <i>Psychiatry (Abingdon, England)</i> , <b>2007</b> , 6, 305-308		3
187	A translational, caffeine-induced model of onset insomnia in rats and healthy volunteers. <i>Psychopharmacology</i> , <b>2007</b> , 191, 943-50	4.7	46
186	D-Cycloserine and performance under different states of anxiety in healthy volunteers. <i>Psychopharmacology</i> , <b>2007</b> , 193, 579-85	4.7	27
185	Low sensitivity of the positron emission tomography ligand [ <sup>11</sup> C]diprenorphine to agonist opiates. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2007</b> , 322, 661-7	4.7	26
184	Rob Kerwin--an appreciation. <i>Journal of Psychopharmacology</i> , <b>2007</b> , 21, 237	4.6	0
183	A validation of the 7.5% CO <sub>2</sub> model of GAD using paroxetine and lorazepam in healthy volunteers. <i>Journal of Psychopharmacology</i> , <b>2007</b> , 21, 42-9	4.6	67
182	Development and validation of the Generalized Anxiety Disorder Inventory (GADI). <i>Journal of Psychopharmacology</i> , <b>2007</b> , 21, 145-52	4.6	20
181	Management of insomnia: treatments and mechanisms. <i>British Journal of Psychiatry</i> , <b>2007</b> , 191, 195-7	5.4	23
180	Which antidepressants have demonstrated superior efficacy? A review of the evidence. <i>International Clinical Psychopharmacology</i> , <b>2007</b> , 22, 323-9	2.2	103
179	In vitro and in vivo effect of BU99006 (5-isothiocyanato-2-benzofuranyl-2-imidazoline) on I <sub>2</sub> binding in relation to MAO: evidence for two distinct I <sub>2</sub> binding sites. <i>Neuropharmacology</i> , <b>2007</b> , 52, 395-404	5.5	13
178	Blockade of alcohol's amnestic activity in humans by an alpha5 subtype benzodiazepine receptor inverse agonist. <i>Neuropharmacology</i> , <b>2007</b> , 53, 810-20	5.5	97
177	Development of a rational scale to assess the harm of drugs of potential misuse. <i>Lancet, The</i> , <b>2007</b> , 369, 1047-53	4.0	779
176	Evidence-based guidelines for management of attention-deficit/hyperactivity disorder in adolescents in transition to adult services and in adults: recommendations from the British Association for Psychopharmacology. <i>Journal of Psychopharmacology</i> , <b>2007</b> , 21, 10-41	4.6	205
175	The effect of 1-(4,5-dihydro-1H-imidazol-2-yl) isoquinoline on monoamine release and turnover in the rat frontal cortex. <i>Neuroscience Letters</i> , <b>2007</b> , 422, 109-13	3.3	2

174	Seizures in a night club. <i>Lancet, The</i> , <b>2007</b> , 370, 220	4.0	8
173	The other face of depression, reduced positive affect: the role of catecholamines in causation and cure. <i>Journal of Psychopharmacology</i> , <b>2007</b> , 21, 461-71	4.6	253
172	Tryptophan depletion does not modify response to CCK-4 challenge in patients with panic disorder after treatment with citalopram. <i>Psychopharmacology</i> , <b>2006</b> , 186, 107-12	4.7	14
171	Human taste thresholds are modulated by serotonin and noradrenaline. <i>Journal of Neuroscience</i> , <b>2006</b> , 26, 12664-71	6.6	146
170	Acute tryptophan depletion alters gastrointestinal and anxiety symptoms in irritable bowel syndrome. <i>American Journal of Gastroenterology</i> , <b>2006</b> , 101, 2582-7	0.7	29
169	Alcohol alternatives--a goal for psychopharmacology?. <i>Journal of Psychopharmacology</i> , <b>2006</b> , 20, 318-20	4.6	10
168	Generalized anxiety disorder: A comorbid disease. <i>European Neuropsychopharmacology</i> , <b>2006</b> , 16 Suppl 2, S109-18	1.2	58
167	Resolution of sleepiness and fatigue in major depressive disorder: A comparison of bupropion and the selective serotonin reuptake inhibitors. <i>Biological Psychiatry</i> , <b>2006</b> , 60, 1350-5	7.9	183
166	In vitro and ex vivo distribution of [3H]harmaline, an endogenous beta-carboline, in rat brain. <i>Neuropharmacology</i> , <b>2006</b> , 50, 269-76	5.5	51
165	Translocator protein (18kDa): new nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function. <i>Trends in Pharmacological Sciences</i> , <b>2006</b> , 27, 402-9	13.2	1097
164	GABAA Receptors: Subtypes, Regional Distribution, and Function. <i>Journal of Clinical Sleep Medicine</i> , <b>2006</b> , 02,	3.1	73
163	Depleting serotonin enhances both cardiovascular and psychological stress reactivity in recovered patients with anxiety disorders. <i>Journal of Clinical Psychopharmacology</i> , <b>2006</b> , 26, 414-8	1.7	41
162	Imaging alcohol cue exposure in alcohol dependence using a PET 15O-H2O paradigm: results from a pilot study. <i>Addiction Biology</i> , <b>2006</b> , 11, 107-15	4.6	20
161	Autoradiographical distribution of imidazoline binding sites in monoamine oxidase A deficient mice. <i>Journal of Neurochemistry</i> , <b>2006</b> , 96, 1551-9	6	18
160	2-(4,5-Dihydroimidazol-2-yl)benzimidazoles as highly selective imidazoline I2/adrenergic alpha2 receptor ligands. <i>Bioorganic and Medicinal Chemistry</i> , <b>2006</b> , 14, 6679-85	3.4	7
159	The role of dopamine and norepinephrine in depression and antidepressant treatment. <i>Journal of Clinical Psychiatry</i> , <b>2006</b> , 67 Suppl 6, 3-8	4.6	53
158	Consensus statement and research needs: the role of dopamine and norepinephrine in depression and antidepressant treatment. <i>Journal of Clinical Psychiatry</i> , <b>2006</b> , 67 Suppl 6, 46-9	4.6	9
157	GABAA receptors: subtypes, regional distribution, and function. <i>Journal of Clinical Sleep Medicine</i> , <b>2006</b> , 2, S7-11	3.1	43

156	Stimulants: use and abuse in the treatment of attention deficit hyperactivity disorder. <i>Current Opinion in Pharmacology</i> , <b>2005</b> , 5, 87-93	5.1	94
155	Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. <i>Journal of Psychopharmacology</i> , <b>2005</b> , 19, 567-96	4.6	449
154	Overview of diagnosis and drug treatments of anxiety disorders. <i>CNS Spectrums</i> , <b>2005</b> , 10, 49-56	1.8	133
153	Behavioral and cardiovascular effects of 7.5% CO <sub>2</sub> in human volunteers. <i>Depression and Anxiety</i> , <b>2005</b> , 21, 18-25	8.4	90
152	GABA-benzodiazepine receptor function in alcohol dependence: a combined 11C-flumazenil PET and pharmacodynamic study. <i>Psychopharmacology</i> , <b>2005</b> , 180, 595-606	4.7	42
151	Is there cognitive impairment in clinically 'healthy' abstinent alcohol dependence?. <i>Alcohol and Alcoholism</i> , <b>2005</b> , 40, 498-503	3.5	84
150	NICE: The National Institute of Clinical Excellence -- or Eccentricity? Reflections on the Z-drugs as hypnotics. <i>Journal of Psychopharmacology</i> , <b>2005</b> , 19, 125-7	4.6	14
149	Using [11C]diprenorphine to image opioid receptor occupancy by methadone in opioid addiction: clinical and preclinical studies. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2005</b> , 312, 309-15	4.7	57
148	Gamma hydroxy butyrate abuse and dependency. <i>Journal of Psychopharmacology</i> , <b>2005</b> , 19, 195-204	4.6	86
147	The use of sleep measures to compare a new 5HT <sub>1A</sub> agonist with buspirone in humans. <i>Journal of Psychopharmacology</i> , <b>2005</b> , 19, 609-13	4.6	31
146	Acute tryptophan depletion. Part I: rationale and methodology. <i>Australian and New Zealand Journal of Psychiatry</i> , <b>2005</b> , 39, 558-64	2.6	93
145	Acute tryptophan depletion. Part II: clinical effects and implications. <i>Australian and New Zealand Journal of Psychiatry</i> , <b>2005</b> , 39, 565-74	2.6	79
144	Evidence-based guidelines for the pharmacological management of substance misuse, addiction and comorbidity: recommendations from the British Association for Psychopharmacology. <i>Journal of Psychopharmacology</i> , <b>2004</b> , 18, 293-335	4.6	127
143	Invited review: the evolution of antidepressant mechanisms. <i>Fundamental and Clinical Pharmacology</i> , <b>2004</b> , 18, 1-21	3.1	127
142	The clinical use of buprenorphine in opiate addiction: evidence and practice. <i>Acta Neuropsychiatrica</i> , <b>2004</b> , 16, 246-74	3.9	18
141	Acute carbon dioxide exposure in healthy adults: evaluation of a novel means of investigating the stress response. <i>Journal of Neuroendocrinology</i> , <b>2004</b> , 16, 256-64	3.8	88
140	Tryptophan depletion reverses the therapeutic effect of selective serotonin reuptake inhibitors in social anxiety disorder. <i>Biological Psychiatry</i> , <b>2004</b> , 56, 503-9	7.9	74
139	Harmaline and harmalan are bioactive components of classical clonidine-displacing substance. <i>Biochemistry</i> , <b>2004</b> , 43, 16385-92	3.2	35

138	Using sleep to evaluate comparative serotonergic effects of paroxetine and citalopram. <i>European Neuropsychopharmacology</i> , <b>2004</b> , 14, 367-72	1.2	26
137	New directions in the treatment of anxiety disorders. <i>Expert Opinion on Therapeutic Patents</i> , <b>2003</b> , 13, 401-423	6.8	5
136	Death and dependence: current controversies over the selective serotonin reuptake inhibitors. <i>Journal of Psychopharmacology</i> , <b>2003</b> , 17, 355-64	4.6	51
135	Using saccadic eye movements as objective measures of tolerance in methadone dependent individuals during the hydromorphone challenge test. <i>Addiction Biology</i> , <b>2003</b> , 8, 59-66	4.6	12
134	Endogenous beta-carbolines as clonidine-displacing substances. <i>Annals of the New York Academy of Sciences</i> , <b>2003</b> , 1009, 157-66	6.5	41
133	Characterization of [(3)H]harmaline binding to rat whole brain membranes. <i>Annals of the New York Academy of Sciences</i> , <b>2003</b> , 1009, 175-9	6.5	11
132	Relationship between imidazoline(2) sites and monoamine oxidase. <i>Annals of the New York Academy of Sciences</i> , <b>2003</b> , 1009, 353-6	6.5	6
131	Identification of an I(2) binding protein from rabbit brain. <i>Annals of the New York Academy of Sciences</i> , <b>2003</b> , 1009, 364-6	6.5	5
130	In vivo estimation of imidazoline(2) binding site turnover. <i>Annals of the New York Academy of Sciences</i> , <b>2003</b> , 1009, 367-70	6.5	5
129	Behavioral, neuroendocrine and neurochemical effects of the imidazoline I2 receptor selective ligand BU224 in naive rats and rats exposed to the stress of the forced swim test. <i>Psychopharmacology</i> , <b>2003</b> , 167, 195-202	4.7	39
128	2-(4,5-dihydro-1H-imidazol-2-yl)indazole (indazim) derivatives as selective I(2) imidazoline receptor ligands. <i>European Journal of Pharmaceutical Sciences</i> , <b>2003</b> , 20, 201-8	5.1	26
127	Naloxone displacement at opioid receptor sites measured in vivo in the human brain. <i>European Journal of Pharmacology</i> , <b>2003</b> , 459, 217-9	5.3	34
126	Functional connectivity analysis of the neural circuits of opiate craving: "more" rather than "different"?. <i>NeuroImage</i> , <b>2003</b> , 20, 1964-70	7.9	72
125	Increased sympathetic response to standing in panic disorder. <i>Psychiatry Research</i> , <b>2003</b> , 118, 69-79	9.9	41
124	Drugs of Abuse John Q. Wang Humana Press. ISBN: 1-588-29057-3, 2003, 505 pp. with index, \$135.00. <i>Journal of Substance Use</i> , <b>2003</b> , 8, 279-279	0.8	
123	Does the brain noradrenaline network mediate the effects of the CO2 challenge?. <i>Journal of Psychopharmacology</i> , <b>2003</b> , 17, 252-9	4.6	67
122	Mirtazapine induces REM sleep behavior disorder (RBD) in parkinsonism. <i>Neurology</i> , <b>2003</b> , 61, 1161; author reply 1161	6.5	24
121	Distribution of [(3)H]BU224, a selective imidazoline I(2) binding site ligand, in rat brain. <i>European Journal of Pharmacology</i> , <b>2002</b> , 450, 55-60	5.3	15

120	Inhalation of 35% CO <sub>2</sub> results in activation of the HPA axis in healthy volunteers. <i>Psychoneuroendocrinology</i> , <b>2002</b> , 27, 715-29	5	85
119	Imaging the GABA-benzodiazepine receptor subtype containing the alpha5-subunit in vivo with [ <sup>11</sup> C]Ro15 4513 positron emission tomography. <i>Journal of Cerebral Blood Flow and Metabolism</i> , <b>2002</b> , 22, 878-89	7.3	95
118	Generalized anxiety disorder: comorbidity, comparative biology and treatment. <i>International Journal of Neuropsychopharmacology</i> , <b>2002</b> , 5, 315-25	5.8	77
117	Does 5-HT restrain panic? A tryptophan depletion study in panic disorder patients recovered on paroxetine. <i>Journal of Psychopharmacology</i> , <b>2002</b> , 16, 5-14	4.6	73
116	The neuropharmacology of serotonin and noradrenaline in depression. <i>International Clinical Psychopharmacology</i> , <b>2002</b> , 17 Suppl 1, S1-12	2.2	159
115	Randomised controlled study of sleep after nefazodone or paroxetine treatment in out-patients with depression. <i>British Journal of Psychiatry</i> , <b>2002</b> , 180, 528-35	5.4	68
114	5-Isothiocyanato-2-benzofuranyl-2-imidazoline (BU99006) an irreversible imidazoline(2) binding site ligand: in vitro and in vivo characterisation in rat brain. <i>Neuropharmacology</i> , <b>2002</b> , 43, 75-83	5.5	14
113	Changes in regional cerebral blood flow elicited by craving memories in abstinent opiate-dependent subjects. <i>American Journal of Psychiatry</i> , <b>2001</b> , 158, 1680-6	11.9	133
112	Tryptophan depletion and its implications for psychiatry. <i>British Journal of Psychiatry</i> , <b>2001</b> , 178, 399-405	5.4	213
111	New insights into the role of the GABA(A)-benzodiazepine receptor in psychiatric disorder. <i>British Journal of Psychiatry</i> , <b>2001</b> , 179, 390-6	5.4	244
110	Venlafaxine occupation at the noradrenaline reuptake site: in-vivo determination in healthy volunteers. <i>Journal of Psychopharmacology</i> , <b>2001</b> , 15, 9-12	4.6	25
109	beta-carboline binding to imidazoline receptors. <i>Drug and Alcohol Dependence</i> , <b>2001</b> , 64, 203-8	4.9	112
108	Flumazenil challenge in social phobia. <i>Depression and Anxiety</i> , <b>2000</b> , 11, 27-30	8.4	18
107	Probes for imidazoline binding sites: synthesis and evaluation of a selective, irreversible I2 ligand. <i>Bioorganic and Medicinal Chemistry Letters</i> , <b>2000</b> , 10, 605-7	2.9	14
106	The psychobiology of anxiolytic drugs. Part 1: Basic neurobiology <b>2000</b> , 88, 197-212		70
105	The psychobiology of anxiolytic drug. Part 2: Pharmacological treatments of anxiety <b>2000</b> , 88, 213-27		81
104	Sleep changes during long-term treatment of depression with fluvoxamine--a home-based study. <i>Psychopharmacology</i> , <b>2000</b> , 149, 360-5	4.7	31
103	Evaluation of [O-methyl- <sup>11</sup> C]RS-15385-197 as a positron emission tomography radioligand for central alpha2-adrenoceptors. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2000</b> , 27, 475-84	8.8	18

102	Sleep and daytime sleepiness the next day following single night-time dose of fluvoxamine, dothiepin and placebo in normal volunteers. <i>Journal of Psychopharmacology</i> , <b>2000</b> , 14, 378-86	4.6	20
101	Treatment of depression and concomitant anxiety. <i>European Neuropsychopharmacology</i> , <b>2000</b> , 10 Suppl 4, S433-7	1.2	28
100	The psychobiology of posttraumatic stress disorder. <i>Journal of Clinical Psychiatry</i> , <b>2000</b> , 61 Suppl 5, 24-9; discussion 30-2	4.6	16
99	Maintenance pharmacotherapy of unipolar depression. <i>Psychiatric Bulletin</i> , <b>1999</b> , 23, 370-373		2
98	Alcohol and the brain. Pharmacological insights for psychiatrists. <i>British Journal of Psychiatry</i> , <b>1999</b> , 175, 114-9	5.4	80
97	Novel selective compounds for the investigation of imidazoline receptors. <i>Annals of the New York Academy of Sciences</i> , <b>1999</b> , 881, 81-91	6.5	70
96	Comparison of crude methanolic CDS extracts from various tissues. <i>Annals of the New York Academy of Sciences</i> , <b>1999</b> , 881, 92-6	6.5	5
95	Inhibition of central monoamine oxidase by imidazoline <sub>2</sub> site-selective ligands. <i>Annals of the New York Academy of Sciences</i> , <b>1999</b> , 881, 114-7	6.5	36
94	Autoradiography of I <sub>2</sub> receptors in frog brain. <i>Annals of the New York Academy of Sciences</i> , <b>1999</b> , 881, 208-11	6.5	2
93	Assessment of GABA(A)benzodiazepine receptor (GBzR) sensitivity in patients on benzodiazepines. <i>Psychopharmacology</i> , <b>1999</b> , 146, 180-4	4.7	11
92	Anti-oxidant vitamins and mental performance of the elderly <b>1999</b> , 14, 459-471		28
91	The neurobiology of social phobia. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , <b>1999</b> , 249 Suppl 1, S11-8	5.1	34
90	The use of benzodiazepines in anxiety and other disorders. <i>European Neuropsychopharmacology</i> , <b>1999</b> , 9 Suppl 6, S407-12	1.2	54
89	Paroxetine and its uses in psychiatry. <i>British Journal of Hospital Medicine</i> , <b>1999</b> , 60, 353-6		1
88	Care of depressed patients with anxiety symptoms. <i>Journal of Clinical Psychiatry</i> , <b>1999</b> , 60 Suppl 17, 23-7; discussion 46-8	4.6	8
87	Characterisation and localisation of [3H]2-(2-benzofuranyl)-2-imidazoline binding in rat brain: a selective ligand for imidazoline I <sub>2</sub> receptors. <i>European Journal of Pharmacology</i> , <b>1998</b> , 353, 123-35	5.3	72
86	'Seeing through a glass darkly': casting light on imidazoline 'I' sites. <i>Trends in Pharmacological Sciences</i> , <b>1998</b> , 19, 381-90	13.2	232
85	Decreased brain GABA(A)-benzodiazepine receptor binding in panic disorder: preliminary results from a quantitative PET study. <i>Archives of General Psychiatry</i> , <b>1998</b> , 55, 715-20		314

84	Serotonin and panic. <i>British Journal of Psychiatry</i> , <b>1998</b> , 172, 465-71	5.4	86
83	Efficacy of mirtazapine in clinically relevant subgroups of depressed patients. <i>Depression and Anxiety</i> , <b>1998</b> , 7 Suppl 1, 7-10	8.4	2
82	Noradrenergic mechanisms in the prefrontal cortex. <i>Journal of Psychopharmacology</i> , <b>1997</b> , 11, 163-8	4.6	47
81	Adult night terrors and paroxetine. <i>Lancet, The</i> , <b>1997</b> , 350, 185	4.0	31
80	The feasibility of abrupt methadone-buprenorphine transfer in British opiate addicts in an outpatient setting. <i>Addiction Biology</i> , <b>1997</b> , 2, 191-200	4.6	21
79	A pilot controlled study of the effects of flumazenil in posttraumatic stress disorder. <i>Biological Psychiatry</i> , <b>1997</b> , 41, 988-90	7.9	28
78	Identification of ligands selective for central I2-imidazoline binding sites. <i>Neurochemistry International</i> , <b>1997</b> , 30, 47-53	4.4	37
77	Imagery of craving in opiate addicts undergoing detoxification. <i>Drug and Alcohol Dependence</i> , <b>1997</b> , 48, 25-31	4.9	25
76	Mirtazapine: pharmacology in relation to adverse effects. <i>Acta Psychiatrica Scandinavica</i> , <b>1997</b> , 391, 31-76.5		50
75	Anhedonia and chronic mild stress model in depression. <i>Psychopharmacology</i> , <b>1997</b> , 134, 333-6; discussion 371-7	4.7	18
74	Case History 3. <i>Human Psychopharmacology</i> , <b>1997</b> , 12, S39-S40	2.3	
73	The Neurochemistry of Addiction. <i>Human Psychopharmacology</i> , <b>1997</b> , 12, S53-S58	2.3	9
72	Psychopharmacology: An Introduction (3rd edn). By Ren <span style="font-variant: small-caps;">é</span> Spiegel. Chichester: John Wiley. 1996. 295 pp. £45 (hb). ISBN: 0 471 95729 1. <i>British Journal of Psychiatry</i> , <b>1997</b> , 170, 96-96	5.4	
71	Practical pharmacotherapy for anxiety disorders. <i>Advances in Psychiatric Treatment</i> , <b>1997</b> , 3, 65-65		
70	Management of patients with depression associated with anxiety symptoms. <i>Journal of Clinical Psychiatry</i> , <b>1997</b> , 58 Suppl 8, 11-6	4.6	8
69	Noradrenaline in depression: half a century of progress. <i>Journal of Psychopharmacology</i> , <b>1997</b> , 11, S3	4.6	4
68	[3H]2-(2-benzofuranyl)-2-imidazoline: a new selective high affinity radioligand for the study of rabbit brain imidazoline I2 receptors. <i>European Journal of Pharmacology</i> , <b>1996</b> , 304, 221-9	5.3	45
67	Imidazoline binding sites in Huntington's and Parkinson's disease putamen. <i>European Journal of Pharmacology</i> , <b>1996</b> , 301, R19-21	5.3	39

66	Addiction: brain mechanisms and their treatment implications. <i>Lancet, The</i> , <b>1996</b> , 347, 31-6	40	89
65	Benzodiazepine site pharmacokinetic/pharmacodynamic quantification in man: direct measurement of drug occupancy and effects on the human brain in vivo. <i>Neuropharmacology</i> , <b>1996</b> , 35, 1483-91	5.5	41
64	Moclobemide in the treatment of social phobia. <i>International Clinical Psychopharmacology</i> , <b>1996</b> , 11 Suppl 3, 77-82	2.2	24
63	Role of GABA in memory and anxiety. <i>Depression and Anxiety</i> , <b>1996</b> , 4, 100-10	8.4	82
62	Noradrenaline and attention lapses. <i>Nature</i> , <b>1996</b> , 380, 291	50.4	120
61	The psychopharmacology of anxiety. <i>British Journal of Hospital Medicine</i> , <b>1996</b> , 55, 187-91		
60	The effects of clonidine on cardiovascular responses to standing in healthy volunteers. <i>Clinical Autonomic Research</i> , <b>1995</b> , 5, 171-7	4.3	26
59	Functional studies of specific imidazoline-2 receptor ligands. <i>Annals of the New York Academy of Sciences</i> , <b>1995</b> , 763, 125-39	6.5	112
58	A comparison of the effects of phenelzine treatment with moclobemide treatment on cardiovascular reflexes. <i>International Clinical Psychopharmacology</i> , <b>1995</b> , 10, 229-38	2.2	11
57	Psychopharmacology of benzodiazepines—An update. <i>Human Psychopharmacology</i> , <b>1995</b> , 10, S1-S14	2.3	4
56	Inhibition of amine oxidase activity by derivatives that recognize imidazoline I2 sites. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>1995</b> , 272, 681-8	4.7	66
55	A pharmacodynamic study of the alpha 2-adrenergic receptor antagonist ethoxydiazoxan in healthy volunteers. <i>Clinical Pharmacology and Therapeutics</i> , <b>1994</b> , 56, 420-9	6.1	15
54	Anxiolytic Potential of Benzodiazepine Receptor Partial Agonists. <i>CNS Drugs</i> , <b>1994</b> , 1, 305-315	6.7	25
53	Alcohol: the drug. <i>British Medical Bulletin</i> , <b>1994</b> , 50, 5-17	5.4	32
52	Saccadic eye movement parameters in normal subjects. <i>Electroencephalography and Clinical Neurophysiology</i> , <b>1993</b> , 86, 69-74		52
51	Antidepressants and mania: To stop or not to stop?. <i>Human Psychopharmacology</i> , <b>1993</b> , 8, 357-360	2.3	6
50	The effects of electroconvulsive therapy on plasma insulin and glucose in depression. <i>British Journal of Psychiatry</i> , <b>1992</b> , 161, 94-8	5.4	9
49	Panic attacks. A neurochemical overview of models and mechanisms. <i>British Journal of Psychiatry</i> , <b>1992</b> , 160, 165-78	5.4	134

48	Characterization and autoradiographical localization of non-adrenoceptor idazoxan binding sites in the rat brain. <i>British Journal of Pharmacology</i> , <b>1992</b> , 106, 1019-27	8.6	97
47	Are 5-HT receptors or beta-adrenoceptors involved in idazoxan-induced food and water intake?. <i>Neuropharmacology</i> , <b>1992</b> , 31, 1081-7	5.5	7
46	Flumazenil and saccadic eye movements in patients with panic disorder and normal controls. <i>Human Psychopharmacology</i> , <b>1992</b> , 7, 45-50	2.3	6
45	Pharmacology of saccadic eye movements in man. 1. Effects of the benzodiazepine receptor ligands midazolam and flumazenil. <i>Psychopharmacology</i> , <b>1991</b> , 105, 361-7	4.7	73
44	The effects of the $\alpha$ -adrenoceptor antagonist idazoxan on sleep in normal volunteers. <i>Journal of Psychopharmacology</i> , <b>1991</b> , 5, 105-10	4.6	7
43	Acute and chronic idazoxan in normal volunteers: biochemical, physiological and psychological effects. <i>Journal of Psychopharmacology</i> , <b>1991</b> , 5, 396-403	4.6	13
42	Overexcitement and disinhibition. Dynamic neurotransmitter interactions in alcohol withdrawal. <i>British Journal of Psychiatry</i> , <b>1990</b> , 157, 491-9	5.4	74
41	Flumazenil provocation of panic attacks. Evidence for altered benzodiazepine receptor sensitivity in panic disorder. <i>Archives of General Psychiatry</i> , <b>1990</b> , 47, 917-25		222
40	Altered central alpha 2-adrenoceptor sensitivity in panic disorder. <i>Archives of General Psychiatry</i> , <b>1989</b> , 46, 165-9		129
39	Evidence that imipramine-induced postural hypotension may be centrally mediated. <i>Human Psychopharmacology</i> , <b>1988</b> , 3, 181-190	2.3	6
38	Strain differences in response to a benzodiazepine receptor inverse agonist (FG 7142) in mice. <i>Psychopharmacology</i> , <b>1988</b> , 94, 335-6	4.7	33
37	Panic attacks and alcohol withdrawal: can subjects differentiate the symptoms?. <i>Biological Psychiatry</i> , <b>1988</b> , 24, 240-3	7.9	40
36	The effects of chronic ritanserin treatment on sleep and the neuroendocrine response to L-tryptophan. <i>Psychopharmacology</i> , <b>1987</b> , 93, 416-20	4.7	67
35	L-Tryptophan and prolactin release: Evidence for interaction between 5-HT <sub>1</sub> and 5-HT <sub>2</sub> receptors. <i>Human Psychopharmacology</i> , <b>1986</b> , 1, 93-97	2.3	62
34	Abstinence symptoms after withdrawal of tranquillising drugs: is there a common neurochemical mechanism?. <i>Lancet, The</i> , <b>1982</b> , 2, 360-2	4.0	60
33	The anxiogenic action of benzodiazepine antagonists. <i>Neuropharmacology</i> , <b>1982</b> , 21, 1033-7	5.5	246
32	Unusual interactions of benzodiazepine receptor antagonists. <i>Nature</i> , <b>1982</b> , 295, 436-8	50.4	276
31	Learning Perspectives on Anxiety Disorders 245-264		3

30	Specific Phobias105-135		
29	Social Phobia137-155		
28	Epidemiology of Anxiety Disorders1-23		1
27	Panic Disorder: Clinical Course, Morbidity and Comorbidity51-79		3
26	Generalised Anxiety Disorder187-204		2
25	Post-Traumatic Syndromes: Comparative Biology and Psychology205-221		
24	Obsessive-Compulsive Disorder: Diagnostic Considerations and an Epidemiological Update157-168		
23	Genetics of Anxiety Disorders: Part I25-40		
22	Panic Disorder: Pathogenesis and Treatment81-103		1
21	The Experience Sampling Method in Stress and Anxiety Research289-306		3
20	Genetics of Anxiety Disorders: Part II41-50		
19	A Case Study of the 35% CO <sub>2</sub> Challenge339-357		5
18	Obsessive-Compulsive Disorder: Biology and Treatment, a Generation of Progress169-186		
17	Clinical Testing of Anxiolytic Drugs325-337		1
16	The Pharmacology of Human Anxiety309-324		2
15	Why doctors have a moral imperative to prescribe and support medical cannabis—An essay by David Nutt. <i>BMJ, The</i> ,n3114	5-9	5
14	Acute Tryptophan Depletion. Part I: Rationale and Methodology		10
13	Acute Tryptophan Depletion. Part II: Clinical Effects and Implications		6

12	Effects of LSD on music-evoked brain activity	3
11	Effects of external stimulation on psychedelic state neurodynamics	9
10	Altered trajectories in the dynamical repertoire of functional network states under psilocybin	4
9	Neural correlates of the DMT experience as assessed via multivariate EEG	1
8	Current Trends in Cognitive Behaviour Therapy for Anxiety Disorders265-286	
7	Functional Neuroimaging of the Acute Effects of Drugs of Abuse83-104	
6	How Current Drug Laws Impede Research and Clinical Treatments206-214	
5	Decreased brain modularity after psilocybin therapy for depression.	2
4	Pharmacological Treatment of Nocturnal Sleep Disturbances53-66	2
3	Effects of classic psychedelic drugs on turbulent signatures in brain dynamics. <i>Network Neuroscience</i> ,1-42	5.6 0
2	The Psychobiology of Post-Traumatic Stress Disorder223-244	
1	The Tryptophan Depletion Technique in Psychiatric Research359-369	